SGIOY:OTCMKTS
Shionogi 2 ADR Representing 1 Ord Shs
USDÂ 8,81
arrow_upward
+1,50%(+0,13) 1D
13 Okt., 16:00:00 GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for SGIOY...
Open
USDÂ 8,66
High
USDÂ 8,85
Low
USDÂ 8,66
Mkt. cap
2,47Â bn
Avg. vol.
169,23Â k
Volume
118,89Â k
52-wk high
USDÂ 12,00
52-wk low
USDÂ 7,65
Beta
0,07
Shares outstanding
1,78Â mjd
No. of employees
6Â k
Open
USDÂ 8,66
High
USDÂ 8,85
Low
USDÂ 8,66
Mkt. cap
2,47Â bn
Avg. vol.
169,23Â k
Volume
118,89Â k
52-wk high
USDÂ 12,00
52-wk low
USDÂ 7,65
Beta
0,07
Shares outstanding
1,78Â mjd
No. of employees
6Â k
News stories
From web sources and news partners
Yahoo Finance
·
58 minute gelede
Dow, S&P 500, Nasdaq Futures Mixed Amid Rising Oil Prices Ahead Of CPI Data: BAC, RIVN, SLS, GME Stocks In Focus
Simply Wall Street
·
18 minute gelede
Tower Semiconductor (NasdaqGS:TSEM) Moved, What Is Drawing Attention Now?
HDFC Sky
·
20 minute gelede
US Stocks End Mixed as Chip Selloff Hits Nasdaq
Investor's Business Daily
·
20 minute gelede
Tech Futures Rise: Meta, AMD Lead 5 Buys; ASML, CPI Inflation Due
Profile
Shionogi & Company, Limited is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana.
Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.
In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough to become a sole marketing agent for its products in Japan.
Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.
The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.
In June 2023, Shionogi announced its acquisition of Qpex Biopharma for approximately $140m.
On 5 October 2026, Shionogi announced an agreement to acquire IntraBio for US$2 billion through its US subsidiary, Shionogi Inc. Wikipedia
About Shionogi 2 ADR Representing 1 Ord Shs
CEOIsao Teshirogi
Employees6,22Â k
Founded1878
Headquarters-
SectorPharmaceutical industry
Websiteshionogi.com